MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DCTH stock logo

DCTH

Delcath Systems, Inc.

$9.63
0.09
 (0.94%)
Exchange:  NASDAQ
Market Cap:  334.606M
Shares Outstanding:  7.356M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Gerard J. Michel
Full Time Employees:  96
Address: 
1633 Broadway
New York City
NY
10019
US
Website:  https://www.delcath.com
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/08 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,06537,20585,231
Gross Profit1,43031,01773,434
EBITDA-37,783-12,1813,859
Operating Income-38,182-12,410660
Net Income-47,678-26,3862,700

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets38,61376,589123,632
Total Liabilities22,8367,84312,413
Total Stockholders Equity15,77768,746111,219
Total Debt10,1871,038936
Cash and Cash Equivalents12,64632,41243,454

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-31,251-18,68122,516
Capital Expenditure-58-559-1,547
Free Cash Flow-31,309-19,24020,969
Net Income-47,678-26,3862,700
Net Change in Cash87419,71611,042

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)213,577.787Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)237,243.550Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)222,416.800Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-155,732.610Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-140,197.810Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-145,999.960Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)39,447.309Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)45,200.915Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)41,596.179Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)948,789.375Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,053,921.209Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)988,055.451Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.040Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.130Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.990Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.065M  ?P/S
 (TTM)
: 
4.43
?Net Income
 (TTM)
: 
-47678000  ?P/E
 (TTM)
: 
146.59
?Enterprise Value
 (TTM)
: 
334.826M  ?EV/FCF
 (TTM)
: 
15.97
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.03  ?ROIC
 (TTM)
: 
0
?Net Debt
 (TTM)
: 
-10922000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
3.56  ?Current Ratio
 (TTM)
: 
10.92

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate DCTH Intrinsic Value

Common questions about DCTH valuation

Is Delcath Systems, Inc. (DCTH) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Delcath Systems, Inc. (DCTH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DCTH a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DCTH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DCTH’s P/E ratio?

You can see DCTH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DCTH?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DCTH a good long-term investment?

Whether DCTH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DCTH

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.94
MARKETSnap

Trading Metrics:

Open: 9.33   Previous Close: 9.54
Day Low: 9.31   Day High: 9.64
Year Low: 8.12   Year High: 18.23
Price Avg 50: 9.52   Price Avg 200: 10.43
Volume: 286430   Average Volume: 421849

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for
06-04-2026 08:30
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for
Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts
05-03-2026 02:50
Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
13-01-2026 12:22
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
09-01-2026 08:05
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
31-12-2025 08:00
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
Delcath Systems (NASDAQ:DCTH) vs. AngioDynamics (NASDAQ:ANGO) Head-To-Head Survey
11-12-2025 02:14
Delcath Systems (NASDAQ:DCTH) vs. AngioDynamics (NASDAQ:ANGO) Head-To-Head Survey

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read